Brind.

R1 Therapeutics is utilizing expert guidance for its AP306 Phase 2b clinical trials, involving Stanford University School of Medicine.

2 reports, 1 independent Updated Jul 1
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

R1 Therapeutics is utilizing expert guidance for its AP306 Phase 2b clinical trials, involving Stanford University School of Medicine.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story